Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Corynebacterium Infections | 1 | 2015 | 3 | 0.460 |
Why?
|
| Corynebacterium | 1 | 2015 | 9 | 0.460 |
Why?
|
| Cystitis | 1 | 2015 | 13 | 0.460 |
Why?
|
| Urinary Bladder | 1 | 2015 | 250 | 0.400 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2024 | 36 | 0.370 |
Why?
|
| Dyspepsia | 1 | 2008 | 9 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 924 | 0.280 |
Why?
|
| Helicobacter Infections | 1 | 2008 | 37 | 0.280 |
Why?
|
| Helicobacter pylori | 1 | 2008 | 38 | 0.280 |
Why?
|
| Fallopian Tubes | 1 | 2024 | 46 | 0.220 |
Why?
|
| Carcinoma in Situ | 1 | 2024 | 53 | 0.210 |
Why?
|
| Ovarian Neoplasms | 4 | 2024 | 787 | 0.200 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2002 | 11 | 0.190 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2002 | 80 | 0.180 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1804 | 0.180 |
Why?
|
| Histiocytosis | 1 | 2001 | 7 | 0.180 |
Why?
|
| Retroperitoneal Space | 1 | 2001 | 39 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 195 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 285 | 0.170 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 1573 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2001 | 123 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 147 | 0.160 |
Why?
|
| Levonorgestrel | 1 | 2019 | 10 | 0.160 |
Why?
|
| Epithelioid Cells | 1 | 2016 | 13 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2001 | 324 | 0.130 |
Why?
|
| Middle Aged | 14 | 2024 | 27045 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 81 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 1075 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 357 | 0.120 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 2394 | 0.120 |
Why?
|
| Cystoscopy | 1 | 2015 | 37 | 0.110 |
Why?
|
| Sarcoma | 1 | 2016 | 216 | 0.110 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2013 | 14 | 0.110 |
Why?
|
| Aged | 13 | 2019 | 19952 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 2685 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 1136 | 0.100 |
Why?
|
| Handwriting | 1 | 2012 | 6 | 0.100 |
Why?
|
| Medical Audit | 1 | 2012 | 39 | 0.100 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 212 | 0.100 |
Why?
|
| Lymphatic Metastasis | 3 | 2023 | 498 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1992 | 48 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 530 | 0.090 |
Why?
|
| Humans | 22 | 2024 | 92351 | 0.090 |
Why?
|
| Biopsy | 3 | 2016 | 1194 | 0.090 |
Why?
|
| Female | 16 | 2024 | 47901 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2012 | 175 | 0.080 |
Why?
|
| Adult | 10 | 2024 | 27547 | 0.080 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2010 | 21 | 0.080 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2010 | 35 | 0.080 |
Why?
|
| Breast Neoplasms | 4 | 2007 | 3054 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2002 | 160 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2793 | 0.080 |
Why?
|
| Male | 10 | 2016 | 43928 | 0.080 |
Why?
|
| Inflammation | 1 | 2015 | 1024 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2012 | 364 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2008 | 10 | 0.070 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2007 | 3 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2007 | 569 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 6918 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 807 | 0.070 |
Why?
|
| Apoptosis | 2 | 2019 | 1737 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2008 | 70 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 2009 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 1191 | 0.070 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 247 | 0.070 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2006 | 5 | 0.060 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2007 | 118 | 0.060 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 16 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 2 | 1999 | 341 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2003 | 2032 | 0.060 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2006 | 62 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 332 | 0.060 |
Why?
|
| Precancerous Conditions | 2 | 2004 | 200 | 0.060 |
Why?
|
| Karyotype | 1 | 2024 | 34 | 0.050 |
Why?
|
| Cell Biology | 1 | 2004 | 15 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 547 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2024 | 55 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2004 | 165 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 229 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 105 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2002 | 93 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2002 | 83 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2002 | 217 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2008 | 4474 | 0.050 |
Why?
|
| Breast | 1 | 2003 | 289 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 605 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 385 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2004 | 274 | 0.040 |
Why?
|
| Crystallization | 1 | 2001 | 215 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1761 | 0.040 |
Why?
|
| Prognosis | 3 | 2019 | 3872 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2016 | 354 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2002 | 800 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 707 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1999 | 70 | 0.040 |
Why?
|
| Carcinoma, Papillary | 1 | 1999 | 157 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2001 | 708 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2002 | 552 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1720 | 0.040 |
Why?
|
| Adolescent | 2 | 2008 | 9495 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 1999 | 1768 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2016 | 13 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2016 | 47 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1178 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 161 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 299 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 2555 | 0.030 |
Why?
|
| Prostatectomy | 1 | 1999 | 479 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3775 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 299 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 213 | 0.030 |
Why?
|
| Tibia | 1 | 2013 | 78 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 390 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 313 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 8730 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 315 | 0.020 |
Why?
|
| Fibroma | 1 | 2010 | 33 | 0.020 |
Why?
|
| Logistic Models | 2 | 2008 | 1239 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 105 | 0.020 |
Why?
|
| Amniotic Band Syndrome | 1 | 1989 | 3 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 107 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1072 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1398 | 0.020 |
Why?
|
| Survival Analysis | 1 | 1992 | 1512 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 110 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 66 | 0.020 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2007 | 12 | 0.020 |
Why?
|
| Breast Cyst | 1 | 2007 | 4 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 37 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 69 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 163 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 328 | 0.020 |
Why?
|
| Postmenopause | 1 | 2008 | 102 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2015 | 9694 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 899 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 321 | 0.010 |
Why?
|
| Chromogenic Compounds | 1 | 2004 | 5 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2006 | 495 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2004 | 72 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 312 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 152 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2002 | 25 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2002 | 73 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2002 | 79 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 241 | 0.010 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2003 | 102 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2002 | 108 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 306 | 0.010 |
Why?
|
| Mammography | 1 | 2003 | 471 | 0.010 |
Why?
|
| Mitosis | 1 | 1999 | 156 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 675 | 0.010 |
Why?
|
| Antisickling Agents | 1 | 1977 | 4 | 0.010 |
Why?
|
| Hemoglobin, Sickle | 1 | 1977 | 18 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 1999 | 259 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 887 | 0.010 |
Why?
|
| Aspirin | 1 | 1977 | 163 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1997 | 405 | 0.010 |
Why?
|
| RNA | 1 | 1997 | 589 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 28059 | 0.000 |
Why?
|
| Abnormalities, Multiple | 1 | 1989 | 236 | 0.000 |
Why?
|
| Radiography | 1 | 1989 | 794 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1989 | 2506 | 0.000 |
Why?
|
| Hemoglobin A | 1 | 1977 | 8 | 0.000 |
Why?
|
| Oxyhemoglobins | 1 | 1977 | 30 | 0.000 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1977 | 12 | 0.000 |
Why?
|
| Gels | 1 | 1977 | 52 | 0.000 |
Why?
|
| Acetylation | 1 | 1977 | 146 | 0.000 |
Why?
|
| Solubility | 1 | 1977 | 185 | 0.000 |
Why?
|
| Kinetics | 1 | 1977 | 1552 | 0.000 |
Why?
|